Decision boundary
The learner stands at 2011-11-22T00:00:00Z, one second after a conservative knowledge cutoff. Gilead had already signed the definitive Pharmasset agreement; the available decision is whether a public-equity underwriting committee should increase, maintain bounded or reduce Gilead exposure—not whether Gilead should sign. The signed terms were USD 137 cash per share and an announced approximate USD 11 billion value (claim.gilead.cutoff.signed-deal-boundary; evidence.gilead.cutoff.signed-agreement).
The independent report is not assigned the embedded midnight-Pacific timestamp, which predates the SEC announcement and conflicts with the article's content. Because the page labels Nov. 21 without a trustworthy time, src.gilead.cutoff.latimes-reuters is admitted at labeled-date UTC day-end, 2011-11-21T23:59:59Z.
Evidence before interpretation
Gilead reported USD 5,482.116 million of cash, cash equivalents and marketable securities, USD 3,922.836 million of working capital and USD 2,660.903 million of nine-month operating cash flow. Pharmasset reported rounded cash of USD 166.5 million, borrowings of USD 2.6 million, a USD 91.2 million FY2011 net loss and a USD 324.7 million accumulated deficit (claim.gilead.cutoff.financial-base; table.gilead.cutoff.reported-financial-base).
The cutoff model is deliberately descriptive. model-run.gilead.cutoff-descriptive-checks calculates the announced value as 2.006524 times Gilead's reported cash and securities and a USD 5,517.884 million subtraction gap. Neither result is financing capacity, leverage, enterprise value, target price or acquisition return (table.gilead.cutoff.transaction-scale).
Clinical evidence without endpoint collapse
Pharmasset reported 40 of 40 ELECTRON Part 1 subjects with SVR12. It separately reported 6 of 10 Part 2 monotherapy subjects with SVR4. table.gilead.cutoff.clinical-signal preserves both the cohort and follow-up endpoint. The deterministic 100.0000% Part 1 arithmetic is a descriptive fraction, not a controlled estimator, confidence interval, Phase 3 result, broad-genotype conclusion or approval probability (claim.gilead.cutoff.electron-boundary; evidence.pharmasset.cutoff.electron-endpoints).
The favorable signal supported continued pivotal testing. It did not erase the facts that all candidates remained in development, Pharmasset expected no direct product revenue for at least two years if at all, and product-level price, deductions, cost and cash flow were missing (claim.gilead.cutoff.no-product-economics).
Financing, competition and disconfirmation
Gilead said it would use cash, bank debt and senior unsecured notes, expected dilution through 2014 and disclosed no financing condition. The announced 89% premium, loss-making target, pre-approval program and absent executed debt schedule oppose treating headline liquidity as spare acquisition capacity (claim.gilead.cutoff.financing-commitment).
Issuer materials cited an advanced nucleotide, open Phase 3 studies, a targeted 2014 approval, HCV market growth and patent coverage. Independent reporting called the purchase high risk and identified Roche, Bristol-Myers Squibb, Johnson & Johnson and Merck in bidder, partner or development context. Those sources create a disclosed conflict, not a calibrated success probability (conflict.gilead.cutoff.strategic-fit-versus-price-risk).
Recommendation and abstention
Select alternative.gilead.maintain-bounded-exposure. Maintain only an existing bounded position and require executed-financing, regimen-level pivotal, safety, regulatory and product-access gates before increasing exposure or calling PSI-7977 validated (judgment.gilead.cutoff.maintain-bounded-exposure).
Abstain from a target price, asset value, acquisition IRR and conclusion that USD 11 billion was attractive. table.gilead.cutoff.decision-unknowns records the missing capitalization, event price, financing, pivotal, product-net-revenue, cost, tax and cash-flow inputs. Revenue is not acquisition cash flow, and later success cannot repair a cutoff valuation model that does not exist (judgment.gilead.cutoff.valuation-abstention; claim.gilead.cutoff.valuation-abstention).